Abstract: A polypeptide having superoxide dismutase (SOD) activity and/or extracellular vesicles containing SOD is effective for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject. The polypeptide has SOD activity derived from a Bacillus amyloliquefaciens strain and/or extracellular vesicles containing SOD derived from a Bacillus subtillis strain is useful for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject.

Abstract: The present invention relates, in part, to methods of preventing or treating macular degeneration in a subject by co-administering a superoxide dismutase enzyme and probiotic Bacillus sp. spores, especially a Bacillus amyloliquefaciens GF423 or GF424 mutant strain. The present invention also provides pharmaceutical and/or food compositions comprising a superoxide dismutase enzyme and probiotic Bacillus sp. spores.

Abstract: The present invention relates to a signal sequence for expressing a CRM197 protein in Escherichia coli and secreting same into the periplasm, and a use thereof, and more specifically, to: a signal sequence for expressing a CRM197 protein; a nucleic acid for coding the signal sequence; a nucleic acid construct or expression vector comprising the nucleic acid and a CRM197 protein gene; a recombinant microorganism having the nucleic acid construct or expression vector introduced therein; and a CRM197 protein production method comprising a step for culturing the recombinant microorganism.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.

Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.

Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.

Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.

Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.

Abstract: Disclosed is a stepwise automatic orthodontic system and method using an artificial intelligence technique. The method includes: scanning a dental state of a patient by using an intraoral scanner; allowing a server to determine to which group of grouped data of the database the scanned dental data belong; allowing the server to refer to data of the determined group, move a tooth needing orthodontics gradually, and generate a predictive digital orthodontic dental data set; allowing the server to transmit the orthodontic-processed digital orthodontic dental data set of a patient to a 3D printer, and allowing the 3D printer to generate and output a dental orthodontic model; and generating a clear aligner by vacuum-compressing a transparent synthetic resin plate to the generated dental orthodontic model through a vacuum former.

Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.

Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.

Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.

Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.

Abstract: A touch sensor for a curved display includes: a first sensor including a) first sensor patterns arranged on a first flexible plastic substrate so as to be continuous in a first direction and spaced apart from each other by a predetermined interval in a second direction and b) first dummy patterns arranged between the first sensor patterns on the first flexible plastic substrate; a second sensor including a) second sensor patterns arranged on a second flexible plastic substrate so as to be continuous in the second direction and be spaced apart from each other by a predetermined interval in the first direction and b) second dummy patterns arranged between the second sensor patterns on the second flexible plastic substrate; and an adhering part causing the first sensor and the second sensor to adhere to each other.

Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.

Abstract: A spill light removing device includes a first blocker which is located perpendicularly to a stream route of light being irradiated from a light source and blocks a stream of light that is incident to the surface of the first blocker, except on a hole formed on the first blocker; a pass-through tunnel which is connected to the hole and is formed in the same direction to the stream route of light and allows the stream of the light to pass through; and a second blocker which has a irregularity pattern that is formed on a inner wall of the pass-through tunnel and reflects the light that is incident in the deviated direction of the stream route of light.

Abstract: A spill light removing device includes a first blocker which is located perpendicularly to a stream route of light being irradiated from a light source and blocks a stream of light that is incident to the surface of the first blocker, except on a hole formed on the first blocker; a pass-through tunnel which is connected to the hole and is formed in the same direction to the stream route of light and allows the stream of the light to pass through; and a second blocker which has a irregularity pattern that is formed on a inner wall of the pass-through tunnel and reflects the light that is incident in the deviated direction of the stream route of light.

Abstract: A display device includes a red laser light source which irradiates light in wavelength range of 636 nm to 645 nm; and a light projector which modulates and project the light on screen. With a display device according to embodiments of the present disclosure, the projected image may be by using three laser light sources which irradiate red, green and blue light each of which wavelengths is limited to 636 nm to 645 nm, 520 nm to 532 nm or 430 nm to 454 nm.

Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.